Apart from AML, C/EBPβ has been implicated in the development of various malignancies, including multiple myeloma, ALK-positive anaplastic large cell lymphoma [51, 52], tumors of the colon, kidney, brain, stomach, prostate, and the ovaries [53–57] and its expression often correlates with increased malignancy and invasiveness of the tumor cells. Here, ALK is linked to plasma cell myeloma.